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Summary Oxaliplatin (trans-/-diaminocyclohexane oxalatoplatinum; L-OHP) is a new platinum derivative for the treatment of advanced
colorectal cancer. Preclinical data have shown that oxaliplatin is active in a wide range of human and murine tumour cell lines, and has been
found to be non-cross-resistant with cisplatin in various cisplatin-resistant cell lines and tumours. Oxaliplatin in combination with 5-fluorouracil
(5-FU) leads to synergistic antiproliferative activity both in vivo and in vitro. Clinical data have shown that oxaliplatin is active and well
tolerated both as monotherapy and in combination with 5-FU/folinic acid in first- or second-line treatment of patients with metastatic colorectal
cancer. Oxaliplatin has a very good safety profile, and studies have confirmed that peripheral sensory neuropathy is related to the cumulative
dose of oxaliplatin administered and that this neuropathy is generally reversible after discontinuation of treatment. High response rates and
prolonged survival have been achieved in metastatic colorectal cancer patients, even after 5-FU failure.
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antiproliferative activity
Oxaliplatin (trans-/-diaminocyclohexane oxalatoplatinum; L-
OHP) is a new platinum derivative in which oxalate is the
hydrolysable ligand and diaminocyclohexane (DACH) the carrier
(Figure 1). The drug is the first clinically available platinum
derivative that has been approved in France for the treatment
ofadvanced colorectal cancer.
Preclinical data have shown that oxaliplatin is active in a wide
range of human and murine tumour cell lines (Silvestro et al,
1990). The National Cancer Institute's Anticancer Drug Screening
Programme has shown oxaliplatin to have a very different profile
from that ofcisplatin when tested on colon cell lines with no cross-
resistance with cisplatin in most cell lines (Rixe et al, 1996). DNA
adducts of oxaliplatin are not recognized by the DNA mismatch
repairproteins. The combination ofoxaliplatin with otherdrugs, such
as 5-fluorouracil (5-FU) and CPT-I1, can lead to synergistic antipro-
liferative activity in vivo and in vitro (Raymond et al, 1996, 1997).
Five phase I studies have been carried out, involving 122 patients
(Mathe et al, 1986; Caussanel et al, 1990; Extra et al, 1990). From
these studies, it was clear that haematological toxicity was
minimal, with no nephrotoxicity, ototoxicity or alopecia; the dose-
limiting toxicity was a peripheral sensory neuropathy that was
related to the cumulative dose ofoxaliplatin administered, and was
generally reversible after treatment discontinuation. However, the
toxicity profile ofoxaliplatin will be discussed in more detail in the
following paper. The maximal tolerated dose was 200 mg m-2, and
the recommended dose for treating these patients in phase II studies
was 130 mg m-2 every 3 weeks.
Clinical data have shown that oxaliplatin is active and well toler-
ated, both as monotherapy and in combination with 5-FU/folinic
acid (FA), in first- or second-line treatment of metastatic colorectal
cancer patients. Examples of the clinical trials undertaken with
oxaliplatin are outlined below (Levi et al, 1992; Bertheault-
Cvitkovic et al, 1996; Bismuth et al, 1996; Machover et al, 1996;
Becouarn et al, 1997; Giacchetti et al, 1997).
OXALIPLATIN AS MONOTHERAPY
First-line treatment
A phase II multicentre study by Becouarn et al (1997), carried out
in France, investigated the use of oxaliplatin as monotherapy in
38 patients with previously untreated metastatic colorectal cancer.
The primary tumour site was the colon in 30 patients and the
rectum in eight others. The median age of the patients was
67 years and most of the patients had one or two metastatic sites.
Their general status was good. Oxaliplatin was given at a dose of
130 mg m-2 intravenously every 3 weeks. Thirty-seven patients
were evaluable for efficacy.
The results of this study are shown in Table 1. A partial
response was achieved in 10 ofthe 37 evaluable patients, giving an
overall response rate of 27%, which is in line with the rate
expected for 5-FU/leucovorin as first-line treatment. Stable
disease was seen in 38% of patients. Median progression-free
survival was 4.2 months. The 1-year survival rate was 53% and the
median survival was more than 12 months. The level of side-
effects was acceptable. Few patients had grade 3/4 haematotoxi-
city, and 13% had grade 3/4 neurosensory toxicity.
Second-line treatment
Two phase II multicentre studies have evaluated oxaliplatin as
second-line monotherapy in a total of 109 patients with histologi-
cally proven colorectal adenocarcinoma (Machover et al, 1996).
All patients were resistant to 5-FU and had non-resectable metas-
tases, but they were in good general condition. Oxaliplatin was
given at a dose of 130 mg m-2 intravenously every 3 weeks.
The response rate in study I was 11% (95% CI 0.03-0.19) and
10% in study 11(95% CI 0.017-0.180). The stabilization rate was
31% for study I and 42% for study II. Median survival time was
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Figure 1 The chemical structure of oxaliplatin, in comparison with those of cisplatin and carboplatin
10% for the 106 evaluable patients in both trials. Grade 3 periph-
eral neuropathy was seen in 34% ofpatients, and grade 4 in 1%.
COMBINATION THERAPY
First-line treatment
One of the combination studies with oxaliplatin that has recently
been finalized is a study in which 5-FU and FA are given in a
chronomodulated manner (Giacchetti et al, 1997). Two hundred
patients (100 in each group) were randomized to receive either
5-FU 700 mg m-2 day-' plus FA 300 mg m-2 day-' for 5 days
(group A) or 5-FU and FA for 5 days plus oxaliplatin (OXA)
125 mg m-2 on the first day ofeach cycle (group B). Patients in the
5-FU/FA arm were allowed to receive the oxaliplatin combination
when failing on 5-FU/FA alone. Patient characteristics for the two
arms of the trial were similar, with a median age of 61 years and
good performance status.
The expert-reviewed response rate in the combination arm,
5-FU/FA/OXA, was three times higher than that obtained in the
5-FU/FA group (34% vs 12% at 9 weeks; P < 0.001). Progression-
free survival in those patients receiving oxaliplatin increased by
3.7 months (7.9 months vs 4.3 months). Overall survival was
19.4 months in the combination group and 17.6 months in the
5-FU/FA group. The administration of oxaliplatin in group A as
second-line therapy might explain the similarity of survival.
Moreover, 21 patients in the 5-FU/FA/OXA group and 17 in the
5-FU/FA group could undergo potentially curative surgery. In the
second-line group, after administration of 5-FU/FA/OXA, five
more patients had curative surgery, underlining the role of oxali-
platin in the observed prolonged survival.
With respect to toxicity, side-effects with 5-FU/FA were
minimal. With the addition of oxaliplatin, the main problem seen
was diarrhoea, which was possibly related to a cumulative effect
from both drugs. The median number of treatment cycles received
by patients was ten in both groups.
As already seen, an increasingly prevalent therapeutic option in
patients treated with oxaliplatin plus 5-FU/FA is secondary poten-
tially curative surgery. In studies carried out by Levi et al (1992),
Bertheault-Cvitkovic et al (1996) and Giacchetti et al (1997), in
which 20-30% of patients from various trials were referred for
Table 1 Oxaliplatin as a first-line monotherapy
Number of evaluable patients 37
Confirmed response
Complete/partial response 0/10
Overall response rate (%) 27
(95%Cl) (13.8-44.1)
Stable disease (%) 38
Median progression-free survival
(months) 4.2
1-year survival rate (%) 53
Median survival (months) 12+
(range) (1-16+)
Table 2 Oxaliplatin in combination with 5-FU/FA as a second-line treatment
French Extended Access Programme)
5-FU resistant Not 5-FU
resistant
Evaluated patients 370 67
Overall response rate (%) 14.6 17.9
(95% Cl) (11-18) (10-29)
Time to progression (months) 4.3 4.6
(95% Cl) (3.9-4.7) (3.4-5.8)
Survival (months) 9.7 11.1
(95% Cl) (8.5-10.8) (8-4.1)
surgery, the median survival of this group was 3-4 years. These
preliminary results indicate that cure following chemotherapy and
secondary curative surgery could become an important end point
in future trials.
Second-line treatment
There have been many studies on the use ofoxaliplatin as a second-
line treatment, and further trials are ongoing. In a study involving
46patients progressing while on different leucovorin and 5-FU regi-
mens (de Gramont et al, 1997), oxaliplatin (100 mg m-2 on day 1)
was added to the bimonthly combination of 5-FU (1.5-2.0 g m-2),
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48-h infusion, and FA (500 mg m-2), given for 2 h on each of the
2 days. All patients had at least one metastasis, and 15 had two
or more.
The overall response rate in the 46 evaluable patients was 46%
(95% CI 31-60). Stable disease was found in 46% of patients,
median progression-free survival was 7 months, and median survival
17 months.
Another clinically important study is the French Extended
Access Programme, a compassionate-use programme, which was
launched in France before the compound was available on the
market (E Cvitkovic, personal communication). The drug was
given in combination with 5-FU/FA to 437 patients who had been
pretreated with 5-FU. Most patients responded poorly or were
refractory to 5-FU. Overall, the performance status was poorer
than that of patients recruited in other oxaliplatin trials. Yet, the
overall response rate was 14.6% (95% CI 11-18) in patients resis-
tant to 5-FU and 17.9% (95% CI 10-29) in those not resistant
(see Table 2). The median survival time was 9.7 months and
11.1 months, respectively, in the two groups. These survival times
were taken into account in addition to their survival times already
achieved with the first-line treatment.
CONCLUSIONS
In conclusion, clinical trials have shown oxaliplatin to be active as
a single agent, with an overall response rate of 27% in previously
untreated patients, and a rate of 10% in those who had previously
received treatment. As monotherapy, oxaliplatin has a good safety
profile, particularly with regard to digestive and haematological
toxicities; peripheral sensory neuropathy is related to cumulative
dose and is the limiting toxicity. It is generally reversible, although
it may last for prolonged periods oftime.
In combination with 5-FU/FA, oxaliplatin is more effective than
5-FU/FA alone. The addition of full-dose oxaliplatin does not
compromise the dose intensity of5-FU/FA, and the combination is
well tolerated.
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